The transcriptomic response of cells to a drug combination is more than the sum of the responses to the monotherapies

  1. Jennifer EL Diaz
  2. Mehmet Eren Ahsen
  3. Thomas Schaffter
  4. Xintong Chen
  5. Ronald B Realubit
  6. Charles Karan
  7. Andrea Califano
  8. Bojan Losic
  9. Gustavo Stolovitzky  Is a corresponding author
  1. Icahn School of Medicine at Mount Sinai, United States
  2. IBM Research, United States
  3. Columbia University, United States

Abstract

Our ability to discover effective drug combinations is limited, in part by insufficient understanding of how the transcriptional response of two monotherapies results in that of their combination. We analyzed matched time course RNAseq profiling of cells treated with single drugs and their combinations and found that the transcriptional signature of the synergistic combination was unique relative to that of either constituent monotherapy. The sequential activation of transcription factors in time in the gene regulatory network was implicated. The nature of this transcriptional cascade suggests that drug synergy may ensue when the transcriptional responses elicited by two unrelated individual drugs are correlated. We used these results as the basis of a simple prediction algorithm attaining an AUROC of 0.77 in the prediction of synergistic drug combinations in an independent dataset.

Data availability

Raw RNAseq data have been deposited in GEO under accession code GSE149428. Code is available at github.com/jennifereldiaz/drug-synergy.

The following previously published data sets were used

Article and author information

Author details

  1. Jennifer EL Diaz

    Department of Genetics and Genomics Sciences, Icahn School of Medicine at Mount Sinai, New York, United States
    Competing interests
    No competing interests declared.
  2. Mehmet Eren Ahsen

    Department of Genetics and Genomics Sciences, Icahn School of Medicine at Mount Sinai, New York, United States
    Competing interests
    No competing interests declared.
  3. Thomas Schaffter

    IBM Computational Biology Center, IBM Research, Yorktown Heights, United States
    Competing interests
    No competing interests declared.
  4. Xintong Chen

    Department of Genetics and Genomics Sciences, Icahn School of Medicine at Mount Sinai, New York, United States
    Competing interests
    No competing interests declared.
  5. Ronald B Realubit

    Department of Systems Biology, Sulzberger Columbia Genome Center, High Throughput Screening Facility, Columbia University, New York, United States
    Competing interests
    No competing interests declared.
  6. Charles Karan

    Department of Systems Biology, Sulzberger Columbia Genome Center, High Throughput Screening Facility, Columbia University, New York, United States
    Competing interests
    No competing interests declared.
  7. Andrea Califano

    Department of Systems Biology, Department of Biomedical Informatics, Department of Biochemistry and Molecular Biophysics, J.P. Sulzberger Columbia Genome Center, Herbert Irving Comprehensive Cancer, Columbia University, New York, United States
    Competing interests
    Andrea Califano, Dr. Califano is founder, equity holder, consultant, and director of DarwinHealth Inc., a company that has licensed some of the algorithms used in this manuscript from Columbia University. Columbia University is also an equity holder in DarwinHealth Inc..
  8. Bojan Losic

    Icahn Institute for Genomics and Multiscale Biology, Icahn School of Medicine at Mount Sinai, New York, United States
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-3643-4612
  9. Gustavo Stolovitzky

    IBM Computational Biology Center, IBM Research, Yorktown Heights, United States
    For correspondence
    gustavo@us.ibm.com
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-9618-2819

Funding

Internal funding from IBM Research and the Icahn School of Medicine at Mount Sinai to GS

  • Jennifer EL Diaz
  • Mehmet Eren Ahsen
  • Thomas Schaffter
  • Xintong Chen
  • Bojan Losic
  • Gustavo Stolovitzky

National Institutes of Health (NIH T32 GM007280)

  • Jennifer EL Diaz

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Copyright

© 2020, Diaz et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 8,094
    views
  • 819
    downloads
  • 19
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Jennifer EL Diaz
  2. Mehmet Eren Ahsen
  3. Thomas Schaffter
  4. Xintong Chen
  5. Ronald B Realubit
  6. Charles Karan
  7. Andrea Califano
  8. Bojan Losic
  9. Gustavo Stolovitzky
(2020)
The transcriptomic response of cells to a drug combination is more than the sum of the responses to the monotherapies
eLife 9:e52707.
https://doi.org/10.7554/eLife.52707

Share this article

https://doi.org/10.7554/eLife.52707

Further reading

    1. Cell Biology
    Xiaojiao Hua, Chen Zhao ... Yan Zhou
    Research Article

    The β-catenin-dependent canonical Wnt signaling is pivotal in organ development, tissue homeostasis, and cancer. Here, we identified an upstream enhancer of Ctnnb1 – the coding gene for β-catenin, named ieCtnnb1 (intestinal enhancer of Ctnnb1), which is crucial for intestinal homeostasis. ieCtnnb1 is predominantly active in the base of small intestinal crypts and throughout the epithelia of large intestine. Knockout of ieCtnnb1 led to a reduction in Ctnnb1 transcription, compromising the canonical Wnt signaling in intestinal crypts. Single-cell sequencing revealed that ieCtnnb1 knockout altered epithelial compositions and potentially compromised functions of small intestinal crypts. While deletion of ieCtnnb1 hampered epithelial turnovers in physiologic conditions, it prevented occurrence and progression of Wnt/β-catenin-driven colorectal cancers. Human ieCTNNB1 drove reporter gene expression in a pattern highly similar to mouse ieCtnnb1. ieCTNNB1 contains a single-nucleotide polymorphism associated with CTNNB1 expression levels in human gastrointestinal epithelia. The enhancer activity of ieCTNNB1 in colorectal cancer tissues was stronger than that in adjacent normal tissues. HNF4α and phosphorylated CREB1 were identified as key trans-factors binding to ieCTNNB1 and regulating CTNNB1 transcription. Together, these findings unveil an enhancer-dependent mechanism controlling the dosage of Wnt signaling and homeostasis in intestinal epithelia.

    1. Cell Biology
    2. Stem Cells and Regenerative Medicine
    Nathaniel Paul Meyer, Tania Singh ... Diane L Barber
    Research Article

    Our understanding of the transitions of human embryonic stem cells between distinct stages of pluripotency relies predominantly on regulation by transcriptional and epigenetic programs with limited insight on the role of established morphological changes. We report remodeling of the actin cytoskeleton of human embryonic stem cells (hESCs) as they transition from primed to naïve pluripotency which includes assembly of a ring of contractile actin filaments encapsulating colonies of naïve hESCs. Activity of the Arp2/3 complex is required for the actin ring, to establish uniform cell mechanics within naïve colonies, promote nuclear translocation of the Hippo pathway effectors YAP and TAZ, and effective transition to naïve pluripotency. RNA-sequencing analysis confirms that Arp2/3 complex activity regulates Hippo signaling in hESCs, and impaired naïve pluripotency with inhibited Arp2/3 complex activity is rescued by expressing a constitutively active, nuclear-localized YAP-S127A. Moreover, expression of YAP-S127A partially restores the actin filament fence with Arp2/3 complex inhibition, suggesting that actin filament remodeling is both upstream and downstream of YAP activity. These new findings on the cell biology of hESCs reveal a mechanism for cytoskeletal dynamics coordinating cell mechanics to regulate gene expression and facilitate transitions between pluripotency states.